Results 61 to 70 of about 507,510 (307)

Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics.

PLoS Pathogens, 2018
Drug resistant HIV is a major threat to the long-term efficacy of antiretroviral treatment. Around 10% of ART-naïve patients in Europe are infected with drug-resistant HIV type 1.
Denise Kühnert, Roger Kouyos, George Shirreff, Jūlija Pečerska, Alexandra U Scherrer, Jürg Böni, Sabine Yerly, Thomas Klimkait, Vincent Aubert, Huldrych F Günthard, Tanja Stadler, Sebastian Bonhoeffer, Swiss HIV Cohort Study   +12 more
doaj   +1 more source

Pre-treatment and Acquired Antiretroviral Drug Resistance among People Living with HIV in Southwest China [PDF]

Zhongguo quanke yixue
Background The prevalence and epidemiology of pre-treatment drug resistance (PDR) and acquired drug resistance (ADR) among HIV-infected individuals vary considerably in different regions of China. Both types of drug resistance have adverse effects on the
KONG Linghong, XIE Xiaoxin, FU Yanhua, GAN Lin, YANG Xiaoyan, MA Shujing, LONG Hai
doaj   +1 more source

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

Molecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova, Zuzana Kozovska, Ondrej Pos, Kristina Pavlov, Sachin Gulati, Peter Makovicky, Kristina Jakic, Monika Burikova, Eva Sedlackova, Barbora Svitkova, Silvia Tyciakova, Vojtech Bystry, Nicolas Blavet, Boris Tichy, Matej Hrnciar, Jaroslav Budis, Miroslav Tomas, Peter Dubovan, Georgina Kolnikova, Veronika Repaska, Nikoleta Mojzesova, Eva Zomborska, Daniel Pindak, Michal Mego, Tomas Szemes, Miroslava Matuskova   +25 more
wiley   +1 more source

Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases

Viruses, 2023
Despite the great technological and medical advances in fighting viral diseases, new therapies for most of them are still lacking, and existing antivirals suffer from major limitations regarding drug resistance and a limited spectrum of activity. In fact,
Rima Hajjo, Dima A. Sabbah, Osama H. Abusara, Reham Kharmah, Sanaa Bardaweel   +4 more
doaj   +1 more source

Positive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia. [PDF]

, 2007
OBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunological criteria of success remain important questions.
Bartlett, Bartlett, Bourgeois, Calmy, Calmy, Carrieri, Carrieri, Coetzee, Colebunders, Colebunders, Dabis, Ferradini, Gill, Gonzalez de, Grabar, Ivers, Kumarasamy, Laurent, Laurent, Lawn, Lawn, Lawn, Le Moing, Ly, Madec, Marzolini, Orrell, Pasquier, Rouet, Rouzioux, Severe, Tassie, Van Heeswijk, Weidle, Wu, Zhou   +35 more
core   +2 more sources

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

A Retrospective Survey of HIV Drug Resistance Among Patients 1 Year After Initiation of Antiretroviral Therapy at 4 Clinics in Malawi [PDF]

, 2012
In 2004, Malawi began scaling up its national antiretroviral therapy (ART) program. Because of limited treatment options, population-level surveillance of acquired human immunodeficiency virus drug resistance (HIVDR) is critical to ensuring long-term ...
Anthony Harries, Barth, Ben Chilima, Bennett, Bennett, Bethany L. Hedt, Carol Porter, Coetzee, Diane E. Bennett, Eddie Limbambala, Erik Schouten, George Bello, Hedt, Hosseinipour, Joep J. van Oosterhout, Johannessen, John Aberle-Grasse, Jordan, Kamoto, Kamya, Kouanfack, Koyalta, Kundai Moyo, Liu, Maldonado, Marcelin, Marconi, Michael R. Jordan, Mina Hosseinipour, Ministry of Health, Moses Massaquoi, Nellie Wadonda-Kabondo, Nzeyimana, Oyugi, Pillay, Puthanakit, Ralf Weigel, Storn Kabuluzi, Sungkanuparph, Wallis, Yu   +40 more
core   +2 more sources

[Viral drug resistance].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2008
More and more viral infections are treated with antiviral drugs, and resistance against these drugs is steadily increasing. Our aim is to give a general understanding of viral resistance and its clinical significance.This article is based on review of published literature on the subject, international recommendations and our own experience as a ...
Susanne Gjeruldsen, Dudman, Kathrine, Stene-Johansen, Inger Sofie Samdal, Vik   +2 more
openaire   +1 more source

Pre‐analytical optimization of cell‐free DNA and extracellular vesicle‐derived DNA for mutation detection in liquid biopsies

Molecular Oncology, EarlyView.
Pre‐analytical handling critically determines liquid biopsy performance. This study defines practical best‐practice conditions for cell‐free DNA (cfDNA) and extracellular vesicle–derived DNA (evDNA), showing how processing time, storage conditions, tube type, and plasma input volume affect DNA integrity and mutation detection.
Jonas Dohmen, Lucrezia De Santis, Bret M. Stephens, Vincent Bernard, Jörg C. Kalff, Lara Braun, Phillipp Leyendecker, Johannes Röttgen, Daniel Weissinger, Anirban Maitra, Paola A. Guerrero, Alexander Semaan   +11 more
wiley   +1 more source

Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents [version 2; referees: 2 approved]

F1000Research, 2016
Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs).
Sara Kishta, Reem EI-Shenawy, Sobhy Kishta   +2 more
doaj   +1 more source